XELJANZ / XELJANZ XR Drug Interactions

(tofacitinib)

7 DRUG INTERACTIONS

Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.

Table 6: Clinically Relevant Interactions Affecting XELJANZ/XELJANZ XR/XELJANZ Oral Solution When Coadministered with Other Drugs

Strong CP3A4 Inhibitors (e.g., ketoconazole)

Clinical Impact

Increased exposure to tofacitinib

Intervention

Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended
[see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]

Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole)

Clinical Impact

Increased exposure to tofacitinib

Intervention

Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended
[see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]

Strong CYP3A4 Inducers (e.g., rifampin)

Clinical Impact

Decreased exposure to tofacitinib and may result in loss of or reduced clinical response

Intervention

Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended
[see Clinical Pharmacology, Figure 3 (12.3)]

Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)

Clinical Impact

Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA.

Intervention

Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended
[see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)]

Find XELJANZ / XELJANZ XR medical information:

Find XELJANZ / XELJANZ XR medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

XELJANZ / XELJANZ XR Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Drug Interactions

7 DRUG INTERACTIONS

Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.

Table 6: Clinically Relevant Interactions Affecting XELJANZ/XELJANZ XR/XELJANZ Oral Solution When Coadministered with Other Drugs

Strong CP3A4 Inhibitors (e.g., ketoconazole)

Clinical Impact

Increased exposure to tofacitinib

Intervention

Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended
[see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]

Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole)

Clinical Impact

Increased exposure to tofacitinib

Intervention

Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended
[see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]

Strong CYP3A4 Inducers (e.g., rifampin)

Clinical Impact

Decreased exposure to tofacitinib and may result in loss of or reduced clinical response

Intervention

Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended
[see Clinical Pharmacology, Figure 3 (12.3)]

Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)

Clinical Impact

Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA.

Intervention

Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended
[see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)]

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.